WhatsApp
backNews Article

Jubilant Therapeutics Reveals Rapid Platelet Reduction with JBI-802 in Phase 1 Clinical Study at 68th ASH Annual Meeting

Preliminary data show all 15 mg dosage patients achieve significant platelet decline by Week 3; company to host detailed event on December 14, 2026

Jubilant Therapeutics reports preliminary Phase 1 clinical data of JBI-802, a first-in-class oral dual LSD1/HDAC6 inhibitor, showing rapid platelet reduction and durable hematologic control in patients with essential thrombocythemia and related myeloproliferative neoplasms. Data presented at the 68th American Society of Hematology Annual Meeting highlight safety and early efficacy with notable platelet normalization by Week 3.

10 Nov 2026|JUBLPHARMA+0.61%
Jubilant Therapeutics Inc.JUBLPHARMANew Ventures

Jubilant Therapeutics Inc.

New Ventures

Jubilant Therapeutics announced the oral presentation of preliminary Phase 1 clinical data for JBI-802, an oral dual LSD1/HDAC6 inhibitor, demonstrating rapid platelet reductions and durable hematologic control in essential thrombocythemia and related myeloproliferative neoplasms. The data highlight safety and early efficacy from their ongoing Phase 1/2 study featured at the 68th American Society of Hematology Annual Meeting.

The Phase 1/2 open-label multicenter trial evaluates JBI-802’s safety, tolerability, and preliminary efficacy in patients with essential thrombocythemia, polycythemia vera, and related myelodysplastic/myeloproliferative neoplasms with thrombocytosis who have relapsed, are refractory, or intolerant to standard care.

Key findings from 8 patients receiving the 15 mg dose include over 50% platelet reduction or platelet normalization (<400 ×10⁹/L) by Week 3, with a median response time of 15 days. Platelet normalization persisted for up to 46 weeks in patients with more than 12 weeks of follow-up.

Additionally, 7 of 11 patients with leukocytosis treated at 15 mg achieved complete hematologic responses. No dose-limiting toxicities were observed at doses of 5, 7, or 15 mg.

Jubilant Therapeutics plans an event on December 14, 2026, to discuss Phase 1 data and clinical implications, coinciding with the oral presentation at ASH. Further detailed efficacy, safety, and molecular data will be shared during the session.

JBI-802 targets the CoREST complex by dual inhibition of LSD1 and HDAC6, impacting disease-relevant cellular processes including abnormal megakaryocyte differentiation, platelet production, leukocyte proliferation, and inflammatory signaling.

Highlights

  • Phase 1 data presented at 68th ASH Annual Meeting, December 12–15, 2026 in New Orleans and online.
  • All 8 patients at 15 mg dose achieved >50% platelet reduction or normalization by Week 3.
  • Platelet normalization maintained up to 46 weeks in patients with >12 weeks follow-up.
  • No dose-limiting toxicities reported at doses 5, 7, or 15 mg.
  • Seven of 11 patients with leukocytosis achieved complete hematologic response.
  • Jubilant to hold webcast event December 14, 2026, to review clinical data and implications.

Key Data Snapshot

Date of announcementNovember 10, 2026
Dosage where all patients responded15 mg
Median time to platelet response15 days
Platelet normalization threshold<400 ×10⁹/L
Follow-up duration for platelet durability33, 44, and 46 weeks
Number of patients responding at 15 mg dose8 patients
Patients with leukocytosis achieving complete hematologic response7 of 11 patients
Dose-limiting toxicities observedNone at 5, 7, or 15 mg
Study phasePhase 1/2
Clinical trial identifiersJBI-802-02; ACTRN12624000478516; NCT07612280
ASH Annual Meeting datesDecember 12–15, 2026

What happened

  • Jubilant Therapeutics presented preliminary Phase 1 clinical data of JBI-802 at the 68th American Society of Hematology Annual Meeting.
  • The data demonstrate rapid platelet reduction and durable hematologic control in essential thrombocythemia and related myeloproliferative neoplasms.
  • JBI-802 is an oral dual LSD1/HDAC6 inhibitor targeting the CoREST complex.

Key details

  • The Phase 1/2 trial enrolled patients with myeloproliferative neoplasms who were relapsed, refractory, or intolerant to standard care.
  • At 15 mg dose, all patients achieved significant platelet reduction or normalization by Week 3.
  • Platelet normalization was maintained in patients for up to 46 weeks at follow-up.
  • Seven of 11 patients with leukocytosis achieved complete hematologic responses.
  • No dose-limiting toxicities were reported at 5, 7, or 15 mg doses.

Order and execution details

  • The oral presentation is scheduled for December 14, 2026, during the ASH Annual Meeting.
  • Jubilant Therapeutics will host a live webcast event on December 14, 2026, to discuss data and implications.
  • Further efficacy, safety, and molecular data will be shared in oral and poster presentations at the meeting.

Background and context

  • JBI-802 inhibits LSD1 and HDAC6 enzymes, impacting processes linked to disease progression.
  • It is being evaluated specifically for essential thrombocythemia, polycythemia vera, and related myeloproliferative disorders.
  • Jubilant Therapeutics is a clinical-stage biopharmaceutical company focused on precision therapies for myeloproliferative neoplasms.

More News on New Ventures

View all

Latest corporate announcements and market updates in New Ventures.

View all news
Jubilant Therapeutics Reveals Rapid Platelet Reduction | Stockk News